share_log

S-1: General form for registration of securities under the Securities Act of 1933

S-1: General form for registration of securities under the Securities Act of 1933

S-1:證券上市註冊聲明
美股SEC公告 ·  08/19 18:43

牛牛AI助理已提取核心訊息

Cingulate Inc., a biopharmaceutical company, has filed a Form S-1 with the Securities and Exchange Commission (SEC) on August 19, 2024, for a registration statement under the Securities Act of 1933. This filing pertains to the potential sale of up to 1,000,000 shares of common stock by Lincoln Park Capital Fund, LLC (Lincoln Park), a selling stockholder. The shares may be sold from time to time in various types of transactions, including ordinary broker transactions and direct sales. The registration allows for the sale of these shares by Lincoln Park at market prices or at negotiated prices. Cingulate Inc. will not receive any proceeds from the sale of shares by Lincoln Park. The company has previously entered into a Purchase Agreement with Lincoln Park, which allows Cingulate to direct Lincoln Park to purchase up to $12 million of its common stock, subject to certain conditions and limitations. As of the filing date, Cingulate's common stock and warrants are listed on the Nasdaq under the symbols 'CING' and 'CINGW' respectively.
Cingulate Inc., a biopharmaceutical company, has filed a Form S-1 with the Securities and Exchange Commission (SEC) on August 19, 2024, for a registration statement under the Securities Act of 1933. This filing pertains to the potential sale of up to 1,000,000 shares of common stock by Lincoln Park Capital Fund, LLC (Lincoln Park), a selling stockholder. The shares may be sold from time to time in various types of transactions, including ordinary broker transactions and direct sales. The registration allows for the sale of these shares by Lincoln Park at market prices or at negotiated prices. Cingulate Inc. will not receive any proceeds from the sale of shares by Lincoln Park. The company has previously entered into a Purchase Agreement with Lincoln Park, which allows Cingulate to direct Lincoln Park to purchase up to $12 million of its common stock, subject to certain conditions and limitations. As of the filing date, Cingulate's common stock and warrants are listed on the Nasdaq under the symbols 'CING' and 'CINGW' respectively.
生物製藥公司Cingulate Inc已於2024年8月19日向證券交易委員會(SEC)提交了Form S-1申請,申請根據1933年證券法進行登記聲明。本次申請與售出Lincoln Park Capital Fund LLC(Lincoln Park)作爲出售股東最多100萬股普通股的潛在銷售相關。這些股份可以在各種類型的交易中從時間到時間出售,其中包括普通經紀人交易和直接銷售。登記允許Lincoln Park以市場價格或協商價格銷售這些股票。Cingulate Inc將不會從Lincoln Park出售股票中獲得任何收益。該公司以前已與Lincoln Park簽訂了購買協議,該協議允許Cingulate指示Lincoln Park購買不超過1200萬美元的普通股,但受某些條件和限制的限制。截至申報日,Cingulate的普通股和認股權證分別在納斯達克上以符號'CING'和'CINGW'進行交易。
生物製藥公司Cingulate Inc已於2024年8月19日向證券交易委員會(SEC)提交了Form S-1申請,申請根據1933年證券法進行登記聲明。本次申請與售出Lincoln Park Capital Fund LLC(Lincoln Park)作爲出售股東最多100萬股普通股的潛在銷售相關。這些股份可以在各種類型的交易中從時間到時間出售,其中包括普通經紀人交易和直接銷售。登記允許Lincoln Park以市場價格或協商價格銷售這些股票。Cingulate Inc將不會從Lincoln Park出售股票中獲得任何收益。該公司以前已與Lincoln Park簽訂了購買協議,該協議允許Cingulate指示Lincoln Park購買不超過1200萬美元的普通股,但受某些條件和限制的限制。截至申報日,Cingulate的普通股和認股權證分別在納斯達克上以符號'CING'和'CINGW'進行交易。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。